WARSAW, Ind., Aug. 29, 2024 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2024. The cash dividend of $0.24 per share is payable on or about October 31, 2024 to stockholders of record as of the close of business on September 30, 2024.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.
|
Media |
Investors |
|
Heather Zoumas-Lubeski |
Zach Weiner |
|
(445) 248-0577 |
(908) 591-6955 |
SOURCE Zimmer Biomet Holdings, Inc.
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB:…
Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company")…
ARLINGTON, Va.--(BUSINESS WIRE)--The National Evaluation System for health Technology (NEST), an initiative of the Medical…
ARLINGTON, Va., June 2, 2025 /PRNewswire/ -- BioInformatics, a Science and Medicine Group company, has released…
New Collaboration Integrates Low-Cost Cash Pay Options into Scripta's Rx Navigation™ Platform, Supporting Fiduciary Responsibility…
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="101px" width="400px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="12px" width="12px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="1000px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
